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Abstract
Background: Methylation of DNA is a common mechanism for silencing genes, and aberrant
methylation is increasingly being implicated in many diseases such as cancer. There is a need for
robust, inexpensive methods to quantitate methylation across a region containing a number of
CpGs. We describe and validate a rapid, in-tube method to quantitate DNA methylation using the
melt data obtained following amplification of bisulfite modified DNA in a real-time thermocycler.
Methods: We first describe a mathematical method to normalise the raw fluorescence data
generated by heating the amplified bisulfite mod i f i e d  D N A .  F r o m  t h i s  n o r m a l i s e d  d a t a  t h e
temperatures at which melting begins and finishes can be calculated, which reflect the less and more
methylated template molecules present respectively. Also the T50, the temperature at which half
the amplicons are melted, which represents the summative methylation of all the CpGs in the
template mixture, can be calculated. These parameters describe the methylation characteristics of
the region amplified in the original sample.
Results: For validation we used synthesized oligonucleotides and DNA from fresh cells and
formalin fixed paraffin embedded tissue, each with known methylation. Using our quantitation we
could distinguish between unmethylated, partially methylated and fully methylated oligonucleotides
mixed in varying ratios. There was a linear relationship between T50 and the dilution of methylated
into unmethylated DNA. We could quantitate the change in methylation over time in cell lines
treated with the demethylating drug 5-aza-2'-deoxycytidine, and the differences in methylation
associated with complete, clonal o r  n o  l o s s  o f  M G M T  e x p r e s s i o n  i n  f o r m a l i n  f i x e d  p a r a f f i n
embedded tissues.
Conclusion: We have validated a rapid, simple in-tube method to quantify methylation which is
robust and reproducible, utilizes easily designed primers and does not need proprietary algorithms
or software. The technique does not depend on any operator manipulation or interpretation of the
melt curves, and is suitable for use in any laboratory with a real-time thermocycler. The parameters
derived provide an objective description and quantitation of the methylation in a specimen, and can
be used to for statistical comparisons of methylation between specimens.
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Background
Methylation of DNA is a common epigenetic change
which is important for the normal functioning of the cell.
Methylation occurs almost exclusively on cytosines in the
setting of a CpG dinucleotide. Most CpGs are methylated
in the genome, except for those in the majority of CpG
dense regions (CpG islands) found at the 5' end of around
50% of mammalian genes. Abnormal methylation is
implicated in a number of disease processes. This applies
particularly in cancer where there is genome wide
hypomethylation together with hypermethylation of
many CpG islands, which can silence tumor suppressor
genes. There is great interest in assessing methylation
because it may have diagnostic or prognostic value, or be
a predictive marker for therapy. It is therefore important
to have simple, accurate and inexpensive techniques for
measuring methylation, which are suitable for use in a
range of laboratories.
There are a number of qualitative and quantitative meth-
ods for the analysis of methylation, each with its own
advantages and disadvantages [1,2]. Many of these meth-
ods rely on treating the DNA with sodium bisulfite. This
deaminates unmethylated cytosines to uracils while meth-
ylated cytosines remain unchanged, resulting in templates
that differ in sequence between the unmethylated and
methylated forms. Regions can be amplified by PCR using
primers specific for bisulfite modified DNA and, depend-
ing on the design of the assay, the methylation status of
individual CpGs, or of a region containing a number of
CpGs, can then be obtained. Techniques which measure
the methylation at each CpG within a target region
include bisulfite sequencing [3], pyrosequencing [4], and
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) [5]. These tech-
niques are relatively expensive to perform, require multi-
ple steps, are time consuming, or require expensive
hardware that is not readily available in many laborato-
ries. The commonly used methylation-specific PCR (MSP)
[6] does not suffer from these disadvantages, but the
primers are more demanding to design, and the assay only
measures methylation of CpGs located near the 3' end of
the primers.
For many purposes an estimate of the overall methylation
of all CpGs within a region is as useful as knowing the
methylation at specific CpGs. We describe an objective
assessment of overall methylation using melt curve analy-
sis, a technique first described by Ririe to differentiate
between desired and undesired products of a PCR [7]. In
melt curve analysis PCR products are slowly heated in the
presence of double-stand DNA (dsDNA) specific fluores-
cent dyes such as SYBR Green I, LCGreen, SYTO9 or Eva-
Green. With increasing temperature the dsDNA denatures
(melts), releasing the fluorescent dye with a resultant
decrease in the fluorescent signal. The temperature at
which dsDNA melts is determined by factors such as
nucleotide sequence, length and GC/AT ratio. A methyl-
ated sequence of DNA, following bisulfite modification,
will maintain a higher GC/AT ratio and so melt at a higher
temperature than its unmethylated equivalent. Melt curve
analysis can detect a single base difference [8]. Worm
applied this principle to DNA methylation analysis [9],
and a number of variations have since been described,
such as methylation-sensitive high resolution melting
[10] and dissociation analysis [11]. In each of these meth-
ods methylation is assessed visually. In melting curve
analysis-methylation (MCA-Meth) the ratio of methylated
to unmethylated amplicons was calculated from the
respective heights of the derivative peaks (-dF/dT), but
this method of quantitation cannot be applied to samples
containing partially methylated molecules [12].
We describe a simple mathematical approach to generate
normalised melt curves from the raw fluorescence melt
data obtained following PCR. We can then calculate from
the normalised melt curve the melt temperature (T50), the
temperature at which 50% of the molecules in the PCR
product are melted, which reflects the average methyla-
tion of all the CpGs in the region amplified, and the tem-
peratures at which melting begins and is complete, which
reflect the heterogeneity of methylation of the alleles
within the amplified region. These parameters provide an
objective description and quantitation of the homogene-
ous and heterogeneous methylation in a specimen, and
can be used to compare methylation between specimens.
Methods
Primers and oligonucleotides
Primers (Table 1), and oligonucleotide sequences repre-
senting the bisulfite modified fragments of the CDKN2A
promoter (Table 2), were synthesized by GeneWorks
(Thebarton, SA, Australia). Primers for melt curve analysis
were designed to amplify both methylated and unmethyl-
ated bisulfite modified DNA, but not unmodified DNA.
Our primer design guidelines were as follows.
1. They should contain at least one T corresponding to a
non-CpG C within the last three nucleotides at the 3'-end
of the primer, to increase the likelihood of amplification
of only bisulfite modified template.
2. They should not contain CpGs, but when this is una-
voidable the number of CpGs are minimised and placed
as far as possible toward the 5'-end of the primer. In these
cases primers are designed with either an inosine or a
degenerate base (C/T in the forward primer, or G/A in the
reverse primer) so that templates with both methylated
and unmethylated CpGs would be amplified.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
Page 3 of 12
(page number not for citation purposes)
3. There should be limited self-complementarity and lim-
ited complementary sequences between primer pairs.
These parameters can be assessed using freely available
software tools including Oligo Calc: Oligonucleotide
Properties Calculator to test for self-complementarity
http://www.basic.northwestern.edu/biotools/oligo
calc.html) and Amplify (version 3.1.4, http://
engels.genetics.wisc.edu) to test for potential primer-dim-
ers.
4. They should amplify a product which is approximately
80 – 160 bp in length.
5. The primers should be approximately 20 – 30 bp in
length.
6. The primer pairs should have melting temperatures as
similar as possible, but differing by no more than 2°C.
Reference DNA
Bisulfite modified genomic DNA prepared from the lym-
phocytes of healthy donors was used as unmethylated ref-
erence [13]. For the methylated reference, 2 μg of
lymphocyte genomic DNA was treated with 10 U of
M.SssI CpG Methylase (New England BioLabs Inc., Bev-
erly, MA, USA) for 16 h at 37°C in a 50 μL reaction vol-
ume containing 160 μM S-adenosylmethionine and
NEBuffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM
MgCl2, 1 mM dithiothreitol, pH 7.9). Methylase treated
DNA was precipitated with 150 μL of 100% ethanol and
centrifuged for 15 min at 4°C. The ethanol was removed
and the DNA pellet was air-dried under vacuum. The DNA
was resuspended in 18 μL of ultra-pure water (UPW,
Fisher Biotec Australia, West Perth, WA, Australia), and
bisulfite modified.
Cell culture
The esophageal adenocarcinoma cell line OE33 was cul-
tured in RPMI 1640 supplemented with 10% foetal
bovine serum, at 37°C, in air enriched with 5% CO2. Trip-
licate cultures of OE33 were grown for 24 h, then treated
with either 1 μM 5-aza-2'-deoxycytidine (aza) (Sigma-
Aldrich, Saint Louis, MO, USA) or vehicle (0.0027% v/v
final concentration acetic acid) for 48, 72 or 120 h. The
cells were incubated for a further 24 h in fresh medium
not containing aza or vehicle and harvested. The DNA was
isolated using TRIzol (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's instructions.
Colorectal carcinoma tissue specimens
For each colorectal carcinoma (CRC) tissue, two 10 μm
formalin fixed paraffin embedded (FFPE) sections were
de-waxed with xylene, washed with 100% ethanol, re-
hydrated with UPW and air-dried under vacuum. Sections
were then digested in a solution consisting of 20 μL 10
mg/ml proteinase K (Promega, Madison, WI, USA) and
200 μL 100 mM NaCl, 10 mM Tris-HCl, 10 mM EDTA and
0.5% (w/v) sodium dodecyl sulfate for 48 h at 55°C, add-
Table 1: Primers used in this study
Gene Primer sequences 5'-3' Locationa Sizeb CpGsc
CDKN2A Forward-GAAGAAAGAGGAGGGGTTGGTTGGTTATT
Reverse-ACCTACTCTCCCCCTCTCCGCAA
chr9:21964847 – 21964930 84 6
TIMP3 Forward-GGYGGTATTATTTTTTATAAGGATTTG
Reverse-AAACCCCRCCTCRAACTATTAAA
chr22:31527488 – 31527645 158 10
MGMT Forward-IGIGTTTIGGATATGTTGGGATAGTT
Reverse-ACIAAACIACCCAAACACTCACCAAA
chr10:131155461 – 131155570 110 12
Y – C/T
R – A/G
I – inosine
aGenome location, as determined by UCSC Genome Browser Database (GBD, http://genome.ucsc.edu) Human March 2006 (hg18) assembly.
bSize of the PCR product.
cNumber of CpGs in the PCR product between the primer binding sites.
Table 2: Oligonucleotide sequences representing a fragment of the CDKN2A promoter
Oligonucleotide Sequence
Unmethylated gaagaaagaggaggggTtggTtggtTaTTagagggtggggTGgaTTGTGtgTGTtTGgTGgTtgCGgagagggggagagTaggT
Partially methylated gaagaaagaggaggggTtggTtggtTaTTagagggtggggTGgaTTGTGtgCGTtCGgCGgTtgCGgagagggggagagTaggT
Fully methylated gaagaaagaggaggggTtggTtggtTaTTagagggtggggCGgaTCGCGtgCGTtCGgCGgTtgCGgagagggggagagTaggT
The oligonucleotide sequences representing a bisulfite modified fragment of the CDKN2A promoter that were either unmethylated, partially 
methylated, or fully methylated. The sequence to which the primers bind is underlined. The location of the six CpGs between the primer binding 
sites are in bold. Thymines which are generated following bisulfite modification and amplification are capitalised.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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ing 20 μL fresh 10 mg/ml proteinase K after the first 24 h.
Protein was removed by precipitation with 80 μL of 6 M
NaCl. The DNA was precipitated with 700 μL of 100%
ethanol, washed with 70% ethanol, air-dried under vac-
uum and resuspended in 100 μL UPW. This study was
approved by the Research Ethics Committee of the Royal
Adelaide Hospital. The study complied with the appropri-
ate institutional guidelines.
Bisulfite modification
Genomic DNA (2 μg) was bisulfite modified as previously
described [14,15]. Bisulfite modified DNA from lym-
phocytes and cell lines were resuspended in UPW at a vol-
ume of 100 μL, and from FFPE tissue in a volume of 20 μL.
PCR and melt analysis
Bisulfite modified DNA (1 μL) was amplified using
QuantiTect SYBR Green PCR Kit (Qiagen, Hilden, Ger-
many) containing a final concentration of 0.5 μM of each
primer (Table 1) in a final reaction volume of 15 μL. The
primers and PCR conditions were specific for bisulfite
modified DNA, and did not amplify unmodified DNA.
The PCR was performed using a Rotor-Gene 3000
(RG3000, Corbett Life Science, Sydney, NSW, Australia)
with a 95°C activation step for 15 min; 95°C for 30 s,
55°C for 60 s for 45 cycles; and a final extension step of
72°C for 4 min. The melt of the PCR product was per-
formed from 60 to 90°C, rising in 0.5°C increments,
waiting for 30 s at the first step and for 5 s at each step
thereafter, and acquiring fluorescence at each temperature
increment.
Statistics
Two groups were compared using the Wilcoxon-Mann-
Whitney test, and three groups were compared using the
Kruskal-Wallis one-way analysis of variance by ranks [16].
More than three groups were compared with one-way
analysis of variance with Tukey multiple comparison
post-test. All statistics were considered significant when
the two tailed P = 0.05.
Results
Algorithm: analysis of melt curves from raw melt data
A graph of the raw fluorescence plotted against tempera-
ture for a typical melt of dsDNA PCR products using the
RG3000 is shown in Figure 1A. The magnitude of the
starting fluorescence often varies significantly between
samples, making direct comparisons difficult. To facilitate
comparisons, the raw fluorescence data can be normal-
ised, as described below. Figure 1B shows that the graph
of raw melt data for a sample has three distinguishable
phases. In Phase 1 there is a linear decrease in fluorescence
with increasing temperature. This decrease can be repre-
sented mathematically. There is a constant background
amount of fluorescence, and added to this is a linearly
decreasing amount which can be calculated from the
regression line which best fits the fluorescent data over the
linear reduction phase (represented as a solid blue line in
Figure 1B). In Phase 2, the rapid reduction in fluorescence
is a combination of the linear decrease and the melting of
dsDNA. During this phase the observed fluorescence
(F(T)obs) is less than the fluorescence expected from the
Phase 1 alone (F(T)max). In Phase 3, the final plateau
phase, the dsDNA is fully melted and there is no further
decline in fluorescence.
At each temperature point it is possible to calculate how
much fluorescence is lost as a result of melting of the
dsDNA. The amount of fluorescence in the sample at any
given temperature, if the dsDNA does not melt and
assuming that the reduction in fluorescence is linear with
increasing temperature, can be calculated from the extrap-
olation of the regression line of the Phase 1 decline. The
reduction in fluorescence (F(T)melt) due to the melting of
the dsDNA at any given temperature, is the difference
between the fluorescence predicted at that temperature
from the regression line (F(T)max) and the observed value
(F(T)obs), or F(T)melt = F(T)max – F(T)obs.
The normalised fluorescence at any given temperature is
the ratio of the amount of fluorescence observed to the
amount of fluorescence predicted if no melting of the
dsDNA had occurred (F(T)obs/F(T)max), expressed as a
percentage. Normalised fluorescence values can then plot-
ted against temperature as normalised melt curves (Figure
1C). The initial phase is a flat line, as there is no reduction
in fluorescence due to specific dsDNA melting. Reduction
in fluorescence due to specific melting of the dsDNA
begins at the take-off temperature (Tto) and finishes at the
touch down temperature (Ttd), where the fluorescence
reaches background. We calculated these as the 95% and
5% percentile fluorescence respectively, but other values
could be easily used.
Normalising the raw melt data facilitates comparisons
between melt curves of different samples, and to unmeth-
ylated and fully methylated DNA references. Two param-
eters which describe the methylation of the population of
DNA templates for the region amplified can be deter-
mined from the normalised curve. The temperature range
over which melting occurs, the difference between take-
off and touchdown temperatures (Ttd – Tto), will be
greater if there is a mixture of methylated and unmethyl-
ated molecules than if there is a homogeneous popula-
tion, making this a measure of methylation heterogeneity.
The extent of methylation of the population can be
described by the temperature at which half the dsDNA
molecules are melted and half are intact (T50). The higher
the T50, the more the methylation in the DNA popula-
tion. The normalised melt curve and the individualBMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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Raw and normalised melt curves Figure 1
Raw and normalised melt curves. A) Typical examples of raw fluorescence melt curves. Six replicates of an oligonucle-
otide representing a fragment of the unmethylated CDKN2A promoter were amplified using the CDKN2A primers and 
QuantiTect SYBR Green PCR Kit, then melted by increasing the temperature from 60 to 90°C, rising in 0.5°C increments, 
waiting for 30 s at the first step and for 5 s at each step thereafter, acquiring fluorescence at each increment. Raw fluorescence 
was plotted against temperature. The plots show that the magnitude of the starting fluorescence may vary significantly even 
between replicates. B) Graph of raw fluorescence plotted against temperature from one sample from Figure 1A shows that 
there are three distinguishable phases. In Phase 1 there is a linear decrease in fluorescence with increasing temperature (repre-
sented as a solid blue line). In Phase 2 there is a rapid reduction in fluorescence which is a combination of the linear decrease 
and the melting of dsDNA. During Phase 2 the observed fluorescence (F(T)obs) is less than the fluorescence expected from the 
Phase 1 alone (F(T)max). The reduction in fluorescence due to the melting of the dsDNA alone at any given temperature (ver-
tical dotted red line) is the difference between F(T)max and F(T)obs, F(T)melt (solid red line with arrow heads). In Phase 3 the 
dsDNA is fully melted and there is no further decline in fluorescence. C) Normalised melt curves for the six replicates in Fig-
ure 1A. The normalised fluorescence was calculated by the formula F(T)obs/F(T)max at every given temperature increment. 
Normalised fluorescence expressed as a percentage was then plotted against temperature.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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parameters derived from it can be simply computed using
the raw fluorescence data exported from the real-time
thermocyler or other microvolume fluorometer integrated
with a rapid temperature cycler.
Melt curve analysis of synthesised oligonucleotides
We tested the application of this analysis using synthe-
sized oligonucleotides of known methylation. Three dif-
ferent oligonucleotides were synthesised, each
representing a bisulfite modified DNA fragment of the
same region of the CDKN2A promoter but differing in the
extent of methylation, the number of methylated CpGs in
the sequence. These CDKN2A oligonucleotide sequences
are shown in Table 2. The region was 84 nucleotides long,
and contained seven CpGs in total, six CpGs between the
primer binding sites. In the oligonucleotide representing
unmethylated bisulfite modified CDKN2A, the cytosines
of the six CpGs were substituted with thymines. For the
methylated oligonucleotide these cytosines remained as
cytosines. For the partially methylated oligonucleotide
three of the cytosines were substituted with thymines, the
other three remained as cytosines.
Figure 2A shows the derivative peaks (-dF/dT), and Figure
2B the normalised melt curves, calculated as described, for
the PCR products amplified from each of the three oligo-
nucleotides. The general shapes of the -dF/dT plots and
the normalised curves are similar, but they are hotter in
proportion to the extent of methylation. The melt curve
for the partially methylated oligonucleotide (three
cytosines and three thymines) is between that of the
unmethylated and methylated oligonucleotides. The T50,
Tto  and  Tdo  significantly increased with the extent of
methylation (Table 3; P < 0.005 for all comparisons),
demonstrating that differences could be measured
between oligonucleotides which differed by as few as
three methylated CpGs per molecule. The normalised
melt curves did not differ whether the PCR products were
melted immediately at the end of the PCR, or on a subse-
quent day, or had been melted a number of times before,
even though the magnitude of the fluorescence intensity
may have decreased over the time (data not shown).
Next, we investigated the ability of the method to analyse
a mixture of two different oligonucleotides. Unmethyl-
ated oligonucleotide was spiked with either partially or
fully methylated oligonucleotide, amplified and then
melted. Spiking the unmethylated oligonucleotide with
either partially methylated (U/P) or fully methylated (U/
M) oligonucleotide significantly altered the shape of the -
dF/dT (Figure 2C) and the normalised (Figure 2D) melt
curves. The spiking did not significantly alter Tto, but did
significantly increase T50 and Ttd in proportion to the
extent of methylation of the spiked mixture (Table 3; P <
0.005 for all comparisons).
Melt curve analysis of mixtures of methylated and 
unmethylated cell DNA
To determine the relationship between T50 and the ratio
of methylated to unmethylated molecules, we made dilu-
tions of methylated reference DNA into unmethylated ref-
erence DNA. The dilutions were amplified using TIMP3
primers, the products melted, and the melt data normal-
ised (Figure 3A). A visible shift to the right of the unmeth-
ylated reference was observed when 5% of the template
molecules were methylated. There was a linear correlation
between the percentage of methylated molecules in the
mixture and the T50  (Figure 3B). Similar results were
observed for regions of the CDKN2A and MGMT genes,
except that shifts in the melt curves could be detected
when 1% of the template molecules were methylated
(data not shown).
Melt curve analysis of cell line DNA
To validate melt curve analysis in cell line DNA we looked
for a correlation between the melt curve parameters and
the reduction in methylation in a cell line cultured with
the demethylating agent 5-aza-2'-deoxycytidine (aza). We
have previously shown that TIMP3 is methylated in the
OE33 cell line, and that with aza treatment TIMP3 meth-
ylation is reduced and expression increased [14,15]. The
results in Figure 4 show the normalised melt curves for
DNA isolated from cells treated with vehicle or aza for 48,
72 or 120 h. Compared to unmethylated and methylated
reference, all normalised melt curves for vehicle treated
Table 3: T50, Tto, Ttd and Ttd – Tto values for known oligonucleotides
Oligonucleotide T50 Tto Ttd Ttd – Tto
Unmethylated 79.07 ± 0.06 78.48 ± 0.05 80.60 ± 0.06 2.12 ± 0.07
Partially methylated 80.00 ± 0.26 78.85 ± 0.53 82.39 ± 0.17 3.54 ± 0.47
Fully methylated 82.10 ± 0.00 81.13 ± 0.05 84.29 ± 0.03 3.16 ± 0.15
U/P 79.27 ± 0.21 78.30 ± 0.05 81.47 ± 0.18 3.17 ± 0.15
U/M 80.17 ± 0.15 78.45 ± 0.11 83.36 ± 0.19 4.90 ± 0.21
U/P – unmethylated oligonucleotide spiked with partially methylated oligonucleotide.
U/M – unmethylated oligonucleotide spiked with fully methylated oligonucleotide.
All values are the mean ± standard deviation of 3 replicate reactions.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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OE33 gave an intermediate melt, suggesting that OE33
was partially methylated. Incubating the cells with vehicle
for increasing lengths of time did not alter the normalised
melt curves, nor the T50, Tto, or Ttd (Table 4). Treatment
with aza shifted the normalised melt curves to the left,
with the degree of shift increasing with the length of treat-
ment (Figure 4). The shifts in the normalised curves corre-
sponded to a significant reduction in T50, Tto and Ttd
when compared to vehicle. The Tdo – Tto, a measure of
methylation heterogeneity, decreased with length of aza
treatment (Table 4). Methylation was confirmed by
COBRA [13]. Similar shifts in the normalised melt curves
were observed for MGMT (data not shown).
Melt curve analysis of tissue DNA
To demonstrate the utility of our melt analysis for detect-
ing different patterns of methylation in tissue samples,
methylation was measured in bisulfite modified DNA pre-
pared from whole sections of FFPE CRC tissue with varia-
ble expression of MGMT as demonstrated by
immunohistochemistry. Methylation of MGMT is associ-
ated with a reduction of its mRNA and protein expression
in cancer cell lines and tissues [15,17]. Sections were
taken from a single block of tissue that had either no,
clonal, or complete loss of MGMT expression in the tumor
cells. The normalised melt curves for a region of the
MGMT promoter are shown in Figure 5. The CRC with no
Melt curves for CDKN2A oligonucleotides Figure 2
Melt curves for CDKN2A oligonucleotides. Oligonucleotide sequences representing a fragment of bisulfite modified 
unmethylated (U), partially methylated (P) or fully methylated (M) CDKN2A promoter (Table 2) were amplified using the 
CDKN2A primers and melted. The raw fluorescence data was converted to either the negative first derivative of the fluores-
cence with respect to temperature (-dF/dT) (A), or normalised (B), and plotted against temperature. Unmethylated oligonucle-
otide was spiked with either partially (U/P) or fully methylated (U/M) oligonucleotide, amplified using the CDKN2A primers 
and melted. Raw fluorescence data was either converted to -dF/dT (C), or normalised (D) and plotted against temperature. 
Data shown are the mean ± standard deviation of triplicate reactions.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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detectable loss of MGMT expression by immunohisto-
chemistry melted at the lowest temperature, that with
complete loss the highest temperature, and that with
clonal loss melted at an intermediate temperature. The
T50, Tto, Ttd and Ttd – Tto are presented in Table 5. The
T50 significantly increased with increasing loss of expres-
sion. There was no significant difference in the Tto for
unmethylated reference and any CRC tissue. The Tto for
the unmethylated reference and each of the CRC tissues
were significantly less than the methylated reference, indi-
cating the presence of unmethylated molecules in each of
the CRC tissues. This would be expected due to the pres-
ence of stromal and other non-tumor cells in the tissue
section. The Ttd for the methylated reference and each of
the CRC tissues was significantly more than the unmeth-
ylated reference, indicating the presence of methylated
molecules in all the CRC tissues, including the tissue with
no detectable loss of MGMT protein expression. The pat-
terns of methylation were confirmed by direct bisulfite
sequencing (Additional File 1).
Discussion
We describe a simple method to quantitate DNA methyl-
ation using the raw fluorescence melt data obtainable fol-
lowing PCR amplification of bisulfite modified DNA. The
method, which provides a summative measure of methyl-
ation at all the CpGs in the PCR product, is reproducible,
sensitive, and informative whether the methylation in the
region amplified is homogeneous or heterogeneous.
While the differences due to methylation were apparent
visually, key descriptive parameters (T50, Tto, Ttd and Ttd
– Tto) could be calculated mathematically, which permits
statistical analysis of results and eliminates the subjectiv-
ity of visual assessments. We validated the utility of the
method with synthesised oligonucleotides and DNA pre-
pared from fresh cells and formalin fixed paraffin embed-
ded tissues.
In the PCR of bisulfite modified DNA, what were unmeth-
ylated cytosines in the genomic DNA will be amplified as
thymines, and only methylated cytosines will be ampli-
Correlation between percentage of methylated reference and T50 Figure 3
Correlation between percentage of methylated reference and T50. Unmethylated reference (bisulfite modified nor-
mal donor lymphocyte DNA) and methylated reference (bisulfite modified CpG methylase treated normal donor lymphocyte 
DNA) were mixed so that the final percentage of methylated reference in the unmethylated reference was 0%, 5%, 10%, 20%, 
30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. The mixtures were amplified using the TIMP3 primers and melted. A) Graph of 
normalised fluorescence plotted against temperature. Data shown are the mean ± standard deviation of triplicate reactions. B) 
Linear correlation between percentage of methylated reference and T50.
Table 4: T50, Tto, Ttd and Ttd – Tto values for TIMP3 in OE33 
cells treated with vehicle or 5-aza-2'-deoxycytidine
Sample T50 Tto Ttd Ttd – Tto
U ref 75.52 ± 0.07 74.74 ± 0.16 77.36 ± 0.08 2.62 ± 0.24
M ref 78.07 ± 0.23 77.26 ± 0.37 79.83 ± 0.02 2.57 ± 0.35
veh 48 h 76.87 ± 0.18 75.63 ± 0.29 79.37 ± 0.04 3.74 ± 0.29
veh 72 h 76.80 ± 0.11 75.56 ± 0.17 79.33 ± 0.07 3.77 ± 0.19
veh 120 h 76.89 ± 0.18 75.70 ± 0.33 79.34 ± 0.08 3.65 ± 0.36
aza 48 h 75.40 ± 0.66 73.84 ± 1.15 78.90 ± 0.09 5.05 ± 1.12
aza 72 h 75.54 ± 0.42 74.34 ± 0.75 78.69 ± 0.06 4.35 ± 0.74
aza 120 h 75.49 ± 0.33 74.38 ± 0.57 78.45 ± 0.19 4.07 ± 0.64
U ref – unmethylated reference.
M ref – methylated reference.
veh – OE33 esophageal adenocarcinoma cell line treated with vehicle 
for 48, 72 or 120 h.
aza – OE33 esophageal adenocarcinoma cell line treated with 1 μM 5-
aza-2'-deoxycytidine for 48, 72 or 120 h.
Data shown for veh or aza treated OE33 are the mean ± standard 
deviation of triplicate reactions for each of triplicate cultures. Data 
shown for U ref and M ref are the mean ± standard deviation of 
triplicate reactions.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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fied as cytosines. These sequence differences can be distin-
guished by the melt curves of the amplified products. The
temperature range over which melting occurs and the
shape of the curve is a function of the length, sequence
and GC content of the product. Products derived from
DNA template containing methylated cytosines will have
a higher GC content, and so a higher melt temperature
and touch down temperature, than otherwise equivalent
products from DNA with unmethylated cytosines. Simi-
larly, products from unmethylated DNA will have a cooler
melt temperature and lower take off temperature than
otherwise equivalent methylated DNA. The difference
between the take off and touch down temperatures will
reflect the heterogeneity (or uniformity) of methylation in
the template molecules. Melt curve analysis, unlike gel
electrophoresis, can distinguish between products which
are of the same length but have different GC/AT ratios.
Several groups have used the melt curves from PCR prod-
ucts to detect mutations, polymorphisms or methylation.
Worm [9], Akey [18] and Guldberg [19] detected methyl-
ation by comparing the melting temperature (Tm) from
the derivative peaks (-dF/dT) of the melt curves of the PCR
products. While populations containing only methylated
or unmethylated molecules are easily distinguishable by
the difference in Tm, heterogeneous mixtures of unmeth-
ylated, partially methylated and fully methylated mole-
cules are difficult to analyse or compare. Lorente [12]
described a technique called MCA-Meth in which they cal-
culated a ratio of the relative height of the -dF/dT peaks for
unmethylated to methylated molecules. The MCA-Meth is
semi-quantitative, and cannot be used if partially methyl-
ated molecules are present.
Wittwer described a normalisation of the raw data from
high resolution melts made possible with the develop-
ment of the Idaho HR-1 instrument for genotyping and
mutation [8]. To derive the normalised curves the experi-
menter had to select the 100% and 0% fluorescence val-
ues by eye. Sequence alterations, such as due to
methylation, were identified visually by changes in the
shape or position of the normalised curve. Wojdacz [10]
used high resolution melting to measure methylation fol-
lowing amplification in the Rotor-Gene 6000 with SYTO9
dye. Mixtures of fully methylated or fully unmethylated
DNA molecules, but not partially methylated molecules,
were used in the validation of their method. In the analy-
sis the raw melt curves were adjusted, in a manner not
described, so that all the samples had the same starting
and ending fluorescent signal. In these high resolution
melt methods methylation differences between samples
was assessed subjectively, not quantitatively. To the best
of our knowledge, we are the first to describe and validate
a method to quantitate DNA methylation from melt
curves that can be used for samples that contain any mix-
ture of methylated, unmethylated and/or partially meth-
ylated molecules, and does not depend on visual analysis.
Our method is based on normalising the raw melt fluores-
cence data using a simple algorithm which is easily com-
puterised. It is easy to assess methylation visually from the
normalised melt curve, but the power of the method is
that it permits a mathematical analysis of the methyla-
tion. From the normalised melt data we calculate four
parameters which describe the methylation status of the
amplified region. The Tto, the temperature at which melt-
ing begins, reflects the least methylated amplicons
present. The Ttd, the temperature at which the product is
completely melted, reflects the most methylated ampli-
cons present. The Ttd – Tto reflects the heterogeneity of the
amplicons with respect to methylation. If Ttd – Tto is
small, most alleles have a similar amount of methylation,
if it is large then some alleles are high in methylation, oth-
ers low. The T50 is the temperature at which half of the
amplicons are melted, and reflects the sum of all methyl-
ation of all the CpGs in the amplified region. The more
the methylation in a region, the higher the T50. Because
these parameters are derived mathematically, the subjec-
tivity of other melt curve analytical methods is eliminated.
To validate our method we first used synthesised oligonu-
cleotides representing a bisulfite modified sequence from
Normalised melt curves of TIMP3 in OE33 cells treated with  vehicle or 5-aza-2'-deoxycytidine Figure 4
Normalised melt curves of TIMP3 in OE33 cells 
treated with vehicle or 5-aza-2'-deoxycytidine. Tripli-
cate cultures of esophageal adenocarcinoma cell line OE33 
were treated with either vehicle (veh) or 1 μM 5-aza-2'-
deoxycytidine (aza) for 48, 72, or 120 h. Bisulfite modified 
DNA from treated OE33, unmethylated reference (U ref) 
and methylated reference (M ref) was amplified using the 
TIMP3 primers, melted, and the fluorescence normalised. 
Data shown for veh or aza treated OE33 are the mean ± 
standard deviation of triplicate reactions for each of triplicate 
cultures. Data shown for U ref and M ref are the mean ± 
standard deviation of triplicate reactions.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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the CDKN2A promoter in its methylated, unmethylated
and partially methylated form to show that the shape of
the normalised melt curve, and the temperature at which
the melting commenced and was completed, reflected the
degree of methylation of the template alleles. We then
demonstrated the utility of the method in more the com-
plex situation of analysing DNA preparations from fresh
cells and formalin fixed paraffin embedded tissues. Using
lymphocyte DNA methylated with CpG methylase diluted
into unmethylated lymphocyte DNA we showed a linear
relationship between T50 and the percentage of methyl-
ated amplicons in the mixture. The method could unam-
biguously detect methylation in samples containing
between 1–5% of methylated DNA, depending on the tar-
get sequence. We were able to quantitate the anticipated
reduction in methylation (T50) and methylation hetero-
geneity (Ttd – Tto) over time in a cell line treated with the
demethylating agent 5-aza-2'-deoxycytidine. Finally, we
could quantitate differences in methylation associated
with complete, clonal or no loss of expression of MGMT
expression in formalin fixed paraffin embedded tissues.
Our melt analysis of methylation was confirmed by
bisulfite sequencing.
The melt curve analysis is a valuable addition to the meth-
ods available for measuring methylation. The most com-
mon method for the analysis of methylation is
methylation specific PCR (MSP), which uses primers that
are specific for either methylated, or unmethylated,
bisulfite modified DNA. This technique relies on 3' mis-
matching of the PCR primers for specificity. False posi-
tives can occur if the primers are poorly designed or the
PCR is run at too low a temperature, or possibly for too
many cycles. The method is sensitive, but only measures
methylation of one or two CpGs located near the 3' end of
the primers and is not quantitative. Tumors can be classi-
fied as methylated when only a minor percentage of cells
are methylated, or if the bisulfite conversion of the DNA
is incomplete (with some unmethylated cytosines
remaining as cytosines, not being converted to uracils).
Pyrosequencing accurately quantifies DNA methylation
levels for multiple CpG sites within the PCR product, but
it requires more expensive, biotin labeled primers, and a
pyrosequencer in addition to a PCR thermocycler. Methy-
Light is an extremely sensitive and quantitative assay
which uses TaqMan technology to measure methylation,
utilising the cleavage of a dual-labeled fluorogenic hybrid-
ization probe by the 5' nuclease activity of Taq polymerase
during the PCR amplification. The probes are expensive,
and are specific for a particular methylation pattern
within the amplified region. Generally the probes are
designed to detect the fully methylated or fully unmethyl-
ated allele only, not partially methylated alleles. Bisulfite
sequencing is the gold standard for methylation analysis,
but is time consuming and expensive, and its accuracy is
limited by the number of clones which are sequenced.
Melt curve analysis is rapid and cost-effective method to
quantitate DNA methylation when information about the
summative methylation of the amplified region is
required. Unlike MSP, it is quantitative and does not gen-
erate false positives. Unlike pyrosequencing it does not
require equipment other than a PCR thermocycler, and
unlike MethyLight it resolves heterogeneous methylation
and can quantitate mixtures of variably methylated mole-
cules in the same reaction, and does not require specific
probes. It is much quicker than bisulfite sequencing, but
does not provide the same detail about the pattern of
methylation. It is particularly suited to measuring methyl-
ation in CpG rich regions, such as CpG islands associated
with the promoter regions of genes, where it is generally
sufficient to measure average CpG methylation levels
rather than the level for every single CpG [20]. If high res-
olution methylation detail is required, such as can be pro-
vided by bisulfite sequencing, melt curve analysis can be
used to screen for samples or clones which are unmethyl-
ated and do not require further analysis.
Two modifications have the potential to improve the per-
formance of the method, although the principles of the
analysis would not change. Fluorescent dyes such as
SYTO9, LC Green or Eva Green which do not redistribute
during melting may improve the detection of minor
unmethylated populations, increasing sensitivity. Instru-
ments which acquire fluorescence data with greater accu-
racy and over smaller temperature increments (e.g.,
0.01°C compared to 0.5°C with the RG3000 used in this
study) would also be expected to improve the sensitivity
of the assay.
Conclusion
We have developed a rapid, reproducible and cost-effec-
tive in-tube assay to quantitate DNA methylation which
yields significant information about the methylation in
the template DNA. It resolves heterogeneous methylation,
quantitating the total methylation when there are mix-
Table 5: T50, Tto, Ttd and Ttd – Tto values for MGMT in FFPE 
CRC tissues
Sample T50 Tto Ttd Ttd – Tto
U ref 74.17 ± 0.04 73.64 ± 0.04 75.54 ± 0.04 1.90 ± 0.03
M ref 78.70 ± 0.25 78.06 ± 0.37 80.43 ± 0.15 2.36 ± 0.25
No 74.18 ± 0.09 73.54 ± 0.06 77.24 ± 1.01 3.71 ± 0.95
Clonal 75.84 ± 0.21 73.62 ± 0.17 81.12 ± 0.37 7.50 ± 0.31
Complete 76.17 ± 0.07 73.70 ± 0.09 80.32 ± 0.45 6.62 ± 0.40
U ref – unmethylated reference.
M ref – methylated reference.
No, Clonal and Complete – whole sections of FFPE CRC tissue with 
either no, clonal or complete loss of MGMT protein expression in 
tumor cells, as determined by immunohistochemistry.
All values are the mean ± standard deviation of 6 replicate reactions.BMC Cancer 2009, 9:123 http://www.biomedcentral.com/1471-2407/9/123
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tures of fully methylated, partially methylated and
unmethylated molecules in the same reaction, and
requires no extra experimental processing after the PCR
reaction. The primers are as easy to design as for a conven-
tional PCR reaction, and expensive labelled probes are not
required. The mathematical analysis does not rely on pro-
prietary algorithms or software, is simple to computerise,
and eliminates the imprecision in methods which require
visual manipulation and interpretation of melt curves.
The method is sensitive and reproducible for measuring
methylation using SYBR Green I in a commonly used real-
time thermocycler, and so is well suited to most research
or routine laboratories.
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